NCT04424641 - A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 15, 2020

Primary Completion Date

October 29, 2021

Study Completion Date

October 29, 2021

Conditions

Locally Advanced or Metastatic Solid Tumor(s)Prostate CancerEsophageal CancerTriple Negative Breast Cancer (TNBC)Squamous Cell Carcinoma of Head and Neck (SCCHN)Non-small Cell Lung Cancer (NSCLC)Bladder CancerUterine Cancer

Interventions

BIOLOGICAL

GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.

GEN1044 will be administered intravenously in cycles of 21 days.

Trial Locations (6)

2100

Rigshospitalet (Copenhagen University Hospital), Copenhagen

8035

Hospital Universitari Vall d'Hebron, Barcelona

28040

Fundacion Jimenez Diaz, Madrid

37203

Tennesse Oncology, PLLC - Nashville, Nashville

77054

MD Anderson Cancer Center, Houston

5265601

Chaim Sheba Medical Center, Ramat Gan